Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 16,135 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorders Clear all

Conditions: Unresected Stage IIIb to IVM1c Melanoma
Interventions: Talimogene Laherparepvec; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Rosacea, Erythema
Interventions: AGN-199201 Dose A, AGN-199201 Dose B, AGN-199201 Dose C, AGN-199201 Vehicle; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Actinic Keratosis
Interventions: 50 mg of KX2-391 Ointment 1%; Drug
Lead sponsor: Almirall, S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 16
States / cities: Fremont, California • La Mesa, California • Palm Springs, California + 12 more

Conditions: Mastectomy, Breast Cancer
Interventions: Liposomal bupivacaine, Standard bupivacaine, Placebo; Drug · Other
Lead sponsor: Georgetown University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Breast Neoplasms
Interventions: Cisplatin, Carboplatin, Radiation therapy, Mastectomy (recommended but not mandatory); Drug · Radiation · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Arthritis, Juvenile
Interventions: Golimumab, Methotrexate; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 14
States / cities: San Diego, California • Chicago, Illinois • Boston, Massachusetts + 11 more

Conditions: Urticaria
Interventions: Xolair® (Omalizumab); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: Tremelimumab monotherapy, MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 3
States / cities: San Francisco, California • Memphis, Tennessee • Houston, Texas

Conditions: Melanoma, Malignant Melanoma, Metastatic Melanoma
Interventions: 131I-TM601; Drug
Lead sponsor: TransMolecular; Industry
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: Grand Rapids, Michigan • New York, New York • Dallas, Texas

Conditions: Idiopathic Angioedema
Interventions: Omalizumab, Placebos; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Locally Advanced or Metastatic Malignant Solid Tumors
Interventions: ASP2998, Pembrolizumab, Enfortumab Vedotin, Carboplatin; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 428 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 5
States / cities: Celebration, Florida • Hackensack, New Jersey • New Hyde Park, New York + 2 more

Conditions: Skin Laxity (Submental and Neck), Facial Skin Laxity, Submental Tissue Laxity
Interventions: ULTRAFORMER MPT PLUS, Ulthera System; Device
Lead sponsor: CLASSYS Inc.; Industry
Eligibility: 30 Years to 65 Years
Enrollment: 273 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Los Angeles, California • Charlotte, North Carolina • Wilmington, North Carolina + 2 more

Conditions: Solid Tumors
Interventions: INCB001158, Epacadostat, Pembrolizumab; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Birmingham, Alabama • Chicago, Illinois

Conditions: Advanced or Metastatic NRAS-mutant Melanoma
Interventions: Naporafenib, Dacarbazine, Temozolomide, Trametinib; Drug
Lead sponsor: Erasca, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 21
States / cities: Phoenix, Arizona • San Francisco, California • Englewood, Colorado + 18 more

Conditions: Systemic Lupus Erythematosus
Interventions: Virtual Reiki Therapy; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriasis
Interventions: XP23829 400 mg QD, XP 23829 800 mg QD, XP23829 400 mg BID, Placebo; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 31
States / cities: Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 25 more

Conditions: Skin Neoplasms
Interventions: aminolevulinic acid hydrochloride gel, 10%, aminolevulinic acid HCl topical solution, 20%; Combination Product
Lead sponsor: Goldman, Butterwick, Fitzpatrick and Groff; Other
Eligibility: 35 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Diego, California

Conditions: Breast Cancer
Interventions: gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis; Genetic · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC), Small-cell Lung Cancer, Head and Neck Squamous Cell Cancer, Classical Hodgkin Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Urothelial Carcinoma, Microsatellite Instability-High Cancer, Gastric Cancer, Esophageal Cancer, Cervical Cancer, Hepatocellular Carcinoma, Merkel Cell Carcinoma, Brain Metastases, Adult
Interventions: LITT + Pembrolizumab; Combination Product
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Scleroderma
Interventions: Not listed
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Rheumatoid Arthritis
Interventions: LY2439821, Placebo; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 37
States / cities: Peoria, Arizona • La Mesa, California • Palm Desert, California + 34 more

Conditions: Cancer
Interventions: GSK2141795; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: Baltimore, Maryland • Boston, Massachusetts • New York, New York + 3 more

Conditions: Venous Leg Ulcer
Interventions: TTAX01, Profore Compression Therapy, Cadexomer Iodine dressing; Biological · Other
Lead sponsor: BioTissue Holdings, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 6
States / cities: Carlsbad, California • Sylmar, California • North Chicago, Illinois + 3 more

Conditions: Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Localized Breast Carcinoma
Interventions: Lymphedema Management, Questionnaire Administration, Adjuvant breast radiation therapy; Other · Radiation
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma

AGN-199201 for the Treatment of Erythema With Rosacea

Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp

Post-Mastectomy Analgesia Using Exparel (Liposomal) Versus Standard Bupivacaine or Placebo

Neoadjuvant Platinum-based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer

A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy

Effect of Anti-IgE in Chronic Urticaria

Study of Tremelimumab in Patients With Advanced Solid Tumors

A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma

Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Safety and Effectiveness Evaluation of the High-intensity Focused Ultrasound Device for Lifting Lax Submental and Neck Tissue

A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

HEAL-SLE: Holistic Energy for Alleviating Lupus Symptoms

A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

Comparison of Two Modes of Photodynamic Therapy for the Treatment of Actinic Keratosis on the Upper Extremities

Assessment of Candidate Protein Expression in Breast Cancer Specimens

LITT and Pembrolizumab in Recurrent Brain Metastasis

The Scleroderma Biorepository and Pathogenesis Study (STOP Scleroderma)

A Study in Patients With Rheumatoid Arthritis

A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795

Subjects With Non-Healing Venous Leg Ulcers Treated With Standard Care Plus Cryopreserved Human Umbilical Cord (TTAX01)

Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery